ClinicalTrials.gg
RecruitingNCT07191223CoMTBEVUpdated Sep 24, 2025

Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners in France

An observational study in Tick-borne Encephalitis, France, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 8 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Tick-borne encephalitis is a relatively rare disease (approximately 35 cases diagnosed per year), but most cases (86%) are due to contamination in France via a tick bite. Of the 71 cases reported over two years (May 2021 to May 2023), 94% of patients were hospitalized.

It is therefore important to consider and diagnose at the first signs to ensure appropriate follow-up and also to implement primary prevention in endemic/at-risk areas.

02

Conditions studied

  • Tick-borne Encephalitis, France

Keywords

  • Tick-borne encephalitis
  • tick bite
03

In context

Encephalitis, Tick-Borne

51 studies on the registry are indexed under Encephalitis, Tick-Borne; 9 are open to participants now.

This study's planned enrollment of 100 is below the median of 500 across 11 observational studies indexed under Encephalitis, Tick-Borne.

Browse Encephalitis, Tick-Borne studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Doctoral student or in training and practicing in France

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be a doctoral student or in training
  • Practice in France
  • Agree to participate in the survey.

Exclusion criteria

Exclusion Criteria:

- Refusal to participate in the study

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Tick-borne meningoencephalitis knowledge score

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Service des maladies infectieuses et tropicales - CHU de Strasbourg - France
    Strasbourg, 67091, France
    Recruiting
    • Yves HANSMANN, MD, PhD · Contactyves.hansmann@chru-strasbourg.fr · 33 3 69 55 09 78
    • Yves HANSMANN, MD, PhD · Principal investigator
    • Flore MULLER, MD · Principal investigator
    • Aurélie VELAY, MD · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07191223
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Feb 16, 2024
Primary completion
Feb 16, 2026 (estimated)
Completion
Feb 16, 2026 (estimated)
Last update
Sep 24, 2025

Study contacts

Yves HANSMANN, MD
Contact
yves.hansmann@chru-strasbourg.fr
33 3 69 55 09 78

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion